About: Treating Leukemia in the Time of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treating Leukemia in the Time of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treating Leukemia in the Time of COVID-19
Creator	Ravandi, Farhad Kantarjian, Hagop Thompson, Philip Dabaja, Bouthaina Verstovsek, Srdan Bravo, Guillermo Daver, Naval Dinardo, Courtney Garcia-Manero, Guillermo Haematol, Acta Jabbour, Elias Jain, Nitin Kadia, Tapan Konopleva, Marina Paul, Shilpa Pemmaraju, Naveen Rausch, Caitlin Welch, Mary Wierda, William
Source	Medline; PMC
abstract	The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods. The knowledge about COVID-19 is accumulating rapidly. An important distinction is the prevalence of “exposure” versus “clinical infectivity,” which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of clinical infection is <1–2% worldwide. With a mortality rate of 1–5% in COVID-19 patients in the general population and potentially of >30% in patients with cancer, careful consideration should be given to the risk of COVID-19 in leukemia. Instead of reducing patient access to specialized cancer centers and modifying therapies to ones with unproven curative benefit, there is more rationale for less intensive, yet effective therapies that may require fewer clinic visits or hospitalizations. Here, we offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1159/000508199
bibo:pmid	32392559
has license	no-cc
sha1sum (hex)	e1a39658583a2c387c7c6d8d1a9227fad632a8c5
schema:url	https://doi.org/10.1159/000508199
resource representing a document's title	Treating Leukemia in the Time of COVID-19
has PubMed Central identifier	PMC7270066
has PubMed identifier	32392559
schema:publication	Acta Haematol
resource representing a document's body	covid:e1a39658583a2c387c7c6d8d1a9227fad632a8c5#body_text
is schema:about of	named entity 'leukemia' named entity 'effective' named entity 'mortality rate' named entity 'risk' named entity 'consideration' named entity 'therapies' named entity 'MODIFYING' named entity 'RISK' named entity 'CONSIDERATION' named entity '1-2' named entity 'tyrosine kinase inhibitors' named entity 'reducing' named entity 'venetoclax' named entity 'therapies' named entity 'COVID-19' named entity 'COVID-19' named entity 'intensive' named entity 'hospitalizations' named entity 'periods' named entity 'poses' named entity 'determine' named entity 'COVID-19' named entity 'Bruton's tyrosine kinase' named entity 'COVID-19' named entity 'FLT3' named entity 'leukemia' named entity 'COVID-19' named entity 'leukemia' named entity 'infection' named entity 'chemotherapy' named entity 'inhibitors' named entity 'steroids' named entity 'inflammation' named entity 'blinatumomab' named entity 'MRD' named entity 'impact of COVID-19' named entity 'all-trans retinoic acid' named entity 'CD20' named entity 'social distancing' named entity 'targeted therapies' named entity 'nelarabine' named entity 'vincristine' named entity 'Wuhan' named entity 'methotrexate' named entity 'COVID' named entity 'Leukemia' named entity 'refractory' named entity 'acute myeloid leukemia' named entity 'platelet transfusion' named entity 'radiation therapy' named entity 'SCT' named entity '1/3' named entity 'nucleoside analog' named entity 'COVID-19 outbreak' named entity 'acalabrutinib' named entity 'intrathecal' named entity 'outpatient setting' named entity 'ursodiol' named entity 'infection' named entity 'mediastinal' named entity 'acute lymphoblastic leukemia' named entity 'intensive therapy' named entity 'myelosuppression'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software